Malaysian osteoporosis patients to benefit from new therapeutic option

KUALA LUMPUR, Oct 25 (Bernama) – Malaysians with postmenopausal osteoporosis will benefit from a new therapeutic option, Binosto®, developed by EffRx Pharmaceuticals SA.

Other than Malaysia, Binosto® is also launched in Singapore and it is marketed by Zuellig Pharma, one of the largest healthcare services group in Asia. In 2019, Binosto® will also be available in other Southeast Asian markets.

Binosto® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of postmenopausal osteoporosis. It reduces the risk of hip, spine and non-spine fractures.

Already available in 15 countries worldwide, Binosto® provides gold-standard fracture risk reduction and offers better upper gastrointestinal safety profile than reported for alendronate tablets.

The Switzerland-based pharmaceutical company said in a statement Binosto® is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus.

It also has the potential to improve adherence to therapy, thereby decreasing the risk of disabling fractures.

EffRx Commercial Director, Michael Schmid said: “While growth of Binosto® in our existing markets remains high, geographic expansion through strong local partnerships continues to be a key priority for Binosto® to bring its promise to patients worldwide.”

“With its innovative properties and compelling efficacy and safety evidence, it can be part of many physicians’ toolkit for thousands of osteoporotic patients across Asia”, said Director Marketing Excellence (Asia) at Zuellig Pharma, Frederick Fong.

-- BERNAMA